Abstracts tagged "herbal remedies"

Abstract Number: 1988 • 2018 ACR/ARHP Annual Meeting
Effect of Different Fucoidans on Pathological Pathways Activated in Osteoarthritic Chondrocytes and Synoviocytes
María José Lamas Vázquez¹, Rosa Meijide-Failde¹, Francisco J Blanco², Herminia Domínguez³ and Carlos Vaamonde-Garcia⁴, ¹Department of Physiotherapy, Medicine and Biological Sciences, Tissue Engineering and Regenerative Medicine group (University of A Coruña), A Coruña, Spain, ²Rheumatology Division, CIBER-BBN/ISCIII, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ³Facultad de Ciencias. Campus de Ourense (University of Vigo), Ourense, Spain, ⁴Department of Physiotherapy, Medicine and Biological sciences, Tissue Engineering and Regenerative Medicine group (University of A Coruña), A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is a disease managed rather than cured, with a focus on alleviating its pain. Recent studies show that fucoidans, one of the…
Abstract Number: 2159 • 2017 ACR/ARHP Annual Meeting
Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
Majid Zeidi^1,2, Peter B Chansky^1,2 and Victoria P Werth^3,4, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, PHILADELPHIA, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose : The use of complementary and alternative medicine (CAM) has gained popularity in the United States over the last few decades. Herbal supplements have…
Abstract Number: 2420 • 2014 ACR/ARHP Annual Meeting
Quality Assessment of Controlled Trials Evaluating Chinese Herbal Medicine in Patients with Rheumatoid Arthritis: a Systematic Review
Xin Pan^1,2, Maria A. Lopez-Olivo², Pratibha Nayak³ and Maria E. Suarez-Almazor⁴, ¹Department of Rheumatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Chinese herbal medicine (CHM) is a mainstay in the treatment of rheumatoid arthritis (RA) in China. We conducted a systematic review to appraise the…
Abstract Number: 2236 • 2014 ACR/ARHP Annual Meeting
Plant–Derived Products Are Effective for Treatment of OA Pain and Safer Than Other Active Therapies
Laura Laslett, Xingzhong Jin and Graeme Jones, Menzies Research Institute Tasmania, University of Tasmania, HOBART, Australia
Background/Purpose: Osteoarthritis (OA) is a leading cause of chronic disability. There are no approved treatments for modifying the disease course, therefore disease management consists of…
Abstract Number: 1014 • 2014 ACR/ARHP Annual Meeting
Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes
Abdul Haseeb¹ and Tariq Haqqi², ¹Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH, ²Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH
Background/Purpose: There is growing evidence that shows the involvement of IL-6 in cartilage degradation during OA. Significant correlation between IL-6 levels in serum as well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].